# Raziel Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/raziel-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Jerusalem, Israel
- Website: www.raziel-therapy.com
- Total disclosed funding: $22M
- Latest round: Series C (Dec 31, 2024)
- Investors on record: 6

## About

Founded in 2012 and based in Jerusalem, Israel, Raziel Therapeutics Ltd. is a pharmaceutical company that develops drugs for the treatment of obesity and related indications. The company's product, the RZL-012, causes fat cell death at the injection site which results in reduction of fat tissues.

## Funding rounds

- Series C, Dec 31, 2024 — Peregrine Ventures
- Series C, Dec 18, 2019, $22M — Peregrine Ventures, Pontifax Venture Capital, Docor International Management, Quark Venture, Wille AG, Catalyst Fund

## Investors

- Peregrine Ventures (https://capitalatlas.ai/funds/peregrine-ventures) — Series C
- Pontifax Venture Capital (https://capitalatlas.ai/funds/pontifax-venture-capital) — Series C
- Docor International Management (https://capitalatlas.ai/funds/docor-international-management) — Series C
- Quark Venture (https://capitalatlas.ai/funds/quark-venture) — Series C
- Wille AG — Series C
- Catalyst Fund (https://capitalatlas.ai/funds/catalyst-fund) — Series C